dc.contributor |
Háskóli Íslands |
dc.contributor |
University of Iceland |
dc.contributor.author |
Drobnjak, Tijana |
dc.contributor.author |
Meiri, Hamutal |
dc.contributor.author |
Mandalá, Maurizio |
dc.contributor.author |
Huppertz, Berthold |
dc.contributor.author |
Gizurarson, Sveinbjorn |
dc.date.accessioned |
2018-09-25T13:45:33Z |
dc.date.available |
2018-09-25T13:45:33Z |
dc.date.issued |
2018-07 |
dc.identifier.issn |
1177-8881 |
dc.identifier.uri |
https://hdl.handle.net/20.500.11815/856 |
dc.description.abstract |
Introduction: Human placental protein 13 (PP13) is a galectin predominantly expressed by the placenta. Low serum concentrations of PP13 in early pregnancy indicate a higher risk of developing preeclampsia.
Methods: The pharmacokinetic disposition and bioavailability of PP13 were determined by single intravenous and subcutaneous administration to 12 healthy New Zealand White rabbits. The serum pharmacokinetic values were determined by enzyme-linked immunosorbent assay, and are best described by a two-compartment model.
Results: Both volume of distribution and the area under the curve were dose dependent for the intravenous group (p < 0.01). PP13 elimination half-life was also found to be different between the groups (p < 0.01). The bioavailability of PP13 following subcutaneous administration was found to be 57%.
Conclusion: This study shows that the concentration of total PP13 released into the maternal circulation during pregnancy might be much higher than previously estimated. |
dc.description.sponsorship |
The authors thank Hy Laboratories for providing PP13 to this study through support provided by the European Union through the ASPRE project (# 601852). This study was mainly sponsored by Hananjaehf and the Icelandic Research Fund (Rannis; grant number 163403-052). |
dc.format.extent |
1977-1983 |
dc.language.iso |
en |
dc.publisher |
Dove Medical Press Ltd. |
dc.relation.ispartofseries |
Drug Design, Development and Therapy;12 |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Pharmacology |
dc.subject |
Drug Discovery |
dc.subject |
Pharmaceutical Science |
dc.subject |
Lyfjafræði |
dc.subject |
Lyfjaefnafræði |
dc.subject |
Lyfhrifafræði |
dc.title |
Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits |
dc.type |
info:eu-repo/semantics/article |
dcterms.license |
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. |
dc.description.version |
Peer Reviewed |
dc.identifier.journal |
Drug Design, Development and Therapy |
dc.identifier.doi |
10.2147/DDDT.S167926 |
dc.contributor.department |
Lyfjafræðideild (HÍ) |
dc.contributor.department |
Faculty of Pharmaceutical Sciences (UI) |
dc.contributor.school |
Heilbrigðisvísindasvið (HÍ) |
dc.contributor.school |
School of Health Sciences (UI) |